Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Multiple Sclerosis Performance Test: Technical Development and Usability.

Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, Williams JR, Phillips GA, Mullen CC, Freiburger JL, Mourany L, Reece C, Miller DM, Bethoux F, Bermel RA, Krupp LB, Mowry EM, Alberts J, Rudick RA.

Adv Ther. 2019 May 3. doi: 10.1007/s12325-019-00958-x. [Epub ahead of print]

PMID:
31054035
2.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204. [Epub ahead of print]

PMID:
30334474
3.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA.

Lancet Neurol. 2018 Oct;17(10):870-884. doi: 10.1016/S1474-4422(18)30245-X. Epub 2018 Aug 22.

PMID:
30143361
4.

A brief history of NEDA.

Giovannoni G, Bermel R, Phillips T, Rudick R.

Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. No abstract available.

PMID:
29579628
5.

Long-Term Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions.

Zheng Y, Lee JC, Rudick R, Fisher E.

J Neuroimaging. 2018 Mar;28(2):191-198. doi: 10.1111/jon.12480. Epub 2017 Oct 27.

PMID:
29076591
6.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

7.

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.

Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, LaRocca N, Hudson L, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):734-747. doi: 10.1177/1352458517690822. Epub 2017 Feb 16. Review.

8.

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):704-710. doi: 10.1177/1352458517690823. Epub 2017 Feb 16.

9.

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.

Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):721-733. doi: 10.1177/1352458517690821. Epub 2017 Feb 16.

10.

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.

Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):711-720. doi: 10.1177/1352458517690824. Epub 2017 Feb 16.

11.

Processing speed test: Validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting.

Rao SM, Losinski G, Mourany L, Schindler D, Mamone B, Reece C, Kemeny D, Narayanan S, Miller DM, Bethoux F, Bermel RA, Rudick R, Alberts J.

Mult Scler. 2017 Dec;23(14):1929-1937. doi: 10.1177/1352458516688955. Epub 2017 Jan 12.

PMID:
28080262
12.

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

Fisher E, Nakamura K, Lee JC, You X, Sperling B, Rudick RA.

Mult Scler. 2016 Apr;22(5):668-76. doi: 10.1177/1352458515599072. Epub 2015 Aug 3.

PMID:
26238463
13.

The Future of Research in Multiple Sclerosis.

Fox RJ, Rudick RA.

JAMA Neurol. 2015 Aug;72(8):853-4. doi: 10.1001/jamaneurol.2015.0270. No abstract available.

PMID:
26053218
14.

Cognitive impairment in multiple sclerosis: An 18 year follow-up study.

Strober LB, Rao SM, Lee JC, Fischer E, Rudick R.

Mult Scler Relat Disord. 2014 Jul;3(4):473-81. doi: 10.1016/j.msard.2014.03.004. Epub 2014 Apr 13.

PMID:
25877059
15.

Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology.

Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK.

Neurotherapeutics. 2015 Jan;12(1):285. doi: 10.1007/s13311-014-0323-9. No abstract available.

16.

Commonalities and challenges in the development of clinical trial measures in neurology.

Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK.

Neurotherapeutics. 2015 Jan;12(1):151-69. doi: 10.1007/s13311-014-0310-1. Erratum in: Neurotherapeutics. 2015 Jan;12(1):285.

17.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

18.

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA.

JAMA Neurol. 2014 Nov;71(11):1386-93. doi: 10.1001/jamaneurol.2014.1895.

PMID:
25178496
19.

Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical database.

Miller DM, Thompson NR, Cohen JA, Fox RJ, Hartman J, Schwetz K, Conway DS, Rudick RA.

Mult Scler. 2015 Apr;21(4):457-65. doi: 10.1177/1352458514544536. Epub 2014 Aug 11.

PMID:
25112816
20.

The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.

Rudick RA, Miller D, Bethoux F, Rao SM, Lee JC, Stough D, Reece C, Schindler D, Mamone B, Alberts J.

J Vis Exp. 2014 Jun 30;(88):e51318. doi: 10.3791/51318.

21.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

22.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

23.

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

Simon JH, Bermel RA, Rudick RA.

AJNR Am J Neuroradiol. 2014 May;35(5):831-2. doi: 10.3174/ajnr.A3937. Epub 2014 Apr 3. No abstract available.

24.

Assessing treatment response to interferon-β: is there a role for MRI?

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G.

Neurology. 2014 Jan 21;82(3):248-54. doi: 10.1212/WNL.0000000000000036. Epub 2013 Dec 11. Review.

25.

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

Rudick RA, Larocca N, Hudson LD; MSOAC.

Mult Scler. 2014 Jan;20(1):12-7. doi: 10.1177/1352458513503392. Epub 2013 Sep 20. Review.

PMID:
24057430
26.

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.

Rudick RA, Fisher E.

Mult Scler. 2013 Jul;19(8):1003-4. doi: 10.1177/1352458513482385. No abstract available.

PMID:
23818018
27.

MRI lesions: a surrogate for relapses in multiple sclerosis?

Rudick RA, Cutter G.

Lancet Neurol. 2013 Jul;12(7):628-30. doi: 10.1016/S1474-4422(13)70108-X. Epub 2013 Jun 3. No abstract available.

PMID:
23743083
28.

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Erbayat Altay E, Fisher E, Jones SE, Hara-Cleaver C, Lee JC, Rudick RA.

JAMA Neurol. 2013 Mar 1;70(3):338-44.

29.

Author response to comment on "time to integrate clinical and research informatics".

Katzan IL, Rudick RA.

Sci Transl Med. 2013 Apr 3;5(179):179lr1. doi: 10.1126/scitranslmed.3006031.

30.

Author response.

Rudick RA, Miller A.

Neurology. 2013 Feb 19;80(8):777. No abstract available.

PMID:
23544194
31.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.

Ann Neurol. 2013 Jan;73(1):95-103. doi: 10.1002/ana.23758.

PMID:
23378325
32.

Time to integrate clinical and research informatics.

Katzan IL, Rudick RA.

Sci Transl Med. 2012 Nov 28;4(162):162fs41. doi: 10.1126/scitranslmed.3004583.

PMID:
23197569
33.

Measurement and clinical effect of grey matter pathology in multiple sclerosis.

Geurts JJ, Calabrese M, Fisher E, Rudick RA.

Lancet Neurol. 2012 Dec;11(12):1082-92. doi: 10.1016/S1474-4422(12)70230-2. Review.

PMID:
23153407
34.

Natalizumab: bench to bedside and beyond.

Rudick R, Polman C, Clifford D, Miller D, Steinman L.

JAMA Neurol. 2013 Feb;70(2):172-82. doi: 10.1001/jamaneurol.2013.598. Review.

PMID:
23128399
35.

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA.

J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3.

36.

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.

Ontaneda D, LaRocca N, Coetzee T, Rudick R; NMSS MSFC Task Force.

Mult Scler. 2012 Aug;18(8):1074-80. doi: 10.1177/1352458512451512. Epub 2012 Jun 27.

PMID:
22740488
37.

Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis.

Rudick RA, Miller AE.

Neurology. 2012 Jun 12;78(24):1904-6. doi: 10.1212/WNL.0b013e318259e2e2. Epub 2012 May 11. No abstract available.

PMID:
22581931
38.

The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.

Rudick RA.

Neurology. 2012 Aug 7;79(6):498-9. doi: 10.1212/WNL.0b013e318259e13a. Epub 2012 May 9. No abstract available.

PMID:
22573625
39.

MS clinical trials: what can subgroup analyses teach us?

Rudick RA.

Lancet Neurol. 2012 May;11(5):386-8. doi: 10.1016/S1474-4422(12)70066-2. Epub 2012 Apr 10. No abstract available.

PMID:
22494954
40.

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Fox RJ, Rudick RA.

Neurology. 2012 Feb 7;78(6):436-7. doi: 10.1212/WNL.0b013e318245d2d0. Epub 2012 Jan 25. No abstract available.

PMID:
22282644
41.

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Rudick RA.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S18-23. doi: 10.3949/ccjm.78.s2.05.

PMID:
22123928
42.

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Zula JA, Green HC, Ransohoff RM, Rudick RA, Stark GR, van Boxel-Dezaire AH.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19689-94. doi: 10.1073/pnas.1117347108. Epub 2011 Nov 21.

43.

Oral treatment for multiple sclerosis.

Killestein J, Rudick RA, Polman CH.

Lancet Neurol. 2011 Nov;10(11):1026-34. doi: 10.1016/S1474-4422(11)70228-9. Review.

PMID:
22014437
44.

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Rudick RA, Rani MR, Xu Y, Lee JC, Na J, Shrock J, Josyula A, Fisher E, Ransohoff RM.

PLoS One. 2011;6(5):e19262. doi: 10.1371/journal.pone.0019262. Epub 2011 May 13.

45.

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.

Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.

PMID:
21543733
46.

Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.

Hyland M, Rudick RA.

Curr Opin Neurol. 2011 Jun;24(3):255-61. doi: 10.1097/WCO.0b013e3283460542. Review.

PMID:
21455068
47.

Beta-interferon for multiple sclerosis.

Rudick RA, Goelz SE.

Exp Cell Res. 2011 May 15;317(9):1301-11. doi: 10.1016/j.yexcr.2011.03.002. Epub 2011 Mar 21. Review.

PMID:
21396360
48.

Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go.

Rudick RA.

Ann Neurol. 2011 Feb;69(2):234-6. doi: 10.1002/ana.22388. No abstract available.

PMID:
21387367
49.

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

Miller DM, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick RA.

Mult Scler. 2011 Jun;17(6):734-42. doi: 10.1177/1352458510397221. Epub 2011 Feb 7.

PMID:
21300736
50.

Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.

Miller DM, Moore SM, Fox RJ, Atreja A, Fu AZ, Lee JC, Saupe W, Stadtler M, Chakraborty S, Harris CM, Rudick RA.

Telemed J E Health. 2011 Jan-Feb;17(1):5-13. doi: 10.1089/tmj.2010.0133. Epub 2011 Jan 9.

Supplemental Content

Loading ...
Support Center